News | October 23, 2022
Glenmark Life Sciences Q2FY23 PAT slips to Rs. 106.87 Cr
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The IPO comprises a fresh issue of up to Rs. 11,600 million and an offer for sale of up to 7,305,245 equity shares of Rs. 2 each of Glenmark Life Sciences by Glenmark Pharmaceuticals
EBITDA margins expand to 31.3%
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
European operations' revenue grew 58.4% to Rs 599.7 crore
Subscribe To Our Newsletter & Stay Updated
